Drugs and Devices

FDA approves DNA test to help manage CMV infection in organ transplant patients

On July 5, the U.S. Food and Drug Administration approved COBAS AmpliPrep/COBAS TaqMan CMV Test, a DNA viral load test that helps gauge the progress of anti-viral treatment in solid organ transplant patients undergoing cytomegalovirus (CMV) antiviral therapy. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares